Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
October 8, 2015
April 21, 2020
4c23f98f-eaf3-4ed1-8f57-33ea6ba03529
Related Documents
Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Guidance DocumentMarch 13, 2019Center for Drug Evaluation and Research
Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry
Guidance DocumentDecember 29, 2016Center for Drug Evaluation and Research
Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Guidance DocumentAugust 11, 2015Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox